Reader sentiment, not investment advice. One vote per visitor; click again to change it.
Penumbra stock (PEN) sits at $318.64, up 0.09% today. The business is worth $12.55B in the market, good for #760 of 800 on our coverage list.
Over the past 52 weeks it has traded between $221.26 and $362.41, so it sits 12.1% below the top of that range.
Valuation works out to 78.3 times trailing earnings. The median for its industry group is 26.4.
6 analysts follow the stock and the average call is "hold". The mean target, $358.40, sits 12.5% over where the stock trades.
This summary is put together from the numbers on the page and updates when they do. It describes the data; it is not a forecast or a recommendation.
Composite of 3 factors below, ranked against the 800 U.S. stocks BeStock covers.
Cheaper on P/E than most of BeStock’s coverage scores higher.
Trading closer to its 52-week high than most peers scores higher.
6 analysts, consensus Hold.
How this is scored: each factor above is a 0–100 percentile rank against every other stock BeStock covers (or, for Wall Street, against the five-point Strong Buy–Sell scale). The overall grade is the plain average of whichever factors apply to this stock — no factor is weighted more than another. That average maps to a letter: A ≥ 85, B ≥ 70, C ≥ 50, D ≥ 30, otherwise F. Recomputed from the data on this page as prices and filings update — it describes where a stock ranks today, not a forecast, and not a BeStock recommendation to buy or sell.
PEN is not currently one of the 10 holdings in BeStock Momentum, our rules-based momentum strategy.
Since 2020-07-06, the strategy has returned 1524.8% (321.7% for the equal-weight average of BeStock’s coverage over the same stretch). Holdings can change any trading day, not just on a fixed schedule. Backtested performance, updated weekly — not a guarantee of future results, and not a BeStock recommendation.
What Wall Street analysts and Morningstar's fair-value model expect for the stock
Wall Street’s average 12-month target is $358.40, 12.5% above today’s price, with a consensus rating of Hold.
Figures are Wall Street analyst consensus and Morningstar’s independent fair-value model, sourced as noted above.
Quote as of Oct 1, 2026 11:50 am ET. Prices can lag the live tape. This is background information, not a recommendation.
Ranks are among the 800 or so U.S.-listed stocks BeStock covers, recalculated whenever prices refresh. A tile is left out when the measure does not apply, such as yield for a stock that pays no dividend.
Set against the peer table: at 78.3x earnings, PEN looks expensive against the market, and trades 196% above the 26.4x median among Medical Devices names. The two comparisons do not always agree.
$318.64 is the latest print for PEN, a move of +0.09% against yesterday's close of $318.34. Today's low and high so far: $318.28 and $318.93.
Equity value comes to $12.55B at the current price. By that measure it is number 760 of the 800 names in our coverage.
Buyers pay 78.3 times the last twelve months of profit (EPS $4.52).
The year's floor is $221.26 and the ceiling $362.41. Shares are 12.1% away from that ceiling.
Our data shows no dividend paid by Penumbra over the trailing twelve months.
Of 6 analysts, 17% say buy, 83% hold and 0% sell. Price targets average $358.40, with the most cautious at $320.00 and the most optimistic at $374.00.
BeStock publishes market data and analysis for information only. Nothing here is investment advice or a solicitation to buy or sell any security, and none of it is tailored to your financial situation, goals, or risk tolerance. Quotes may be delayed and figures can contain errors; check primary sources before you trade. How we source and calculate these pages.
No comments yet — be the first to weigh in on PEN.